Dr Nur Adila Binti Mokhtar

Dr Nur Adila Mokhtar graduated from the University of Sheffield, United Kingdom, and pursued her postgraduate training in the United Kingdom. She holds the MRCP (UK) and FRCR (UK) qualifications and successfully obtained the Certificate of Completion of Specialty Training (CCT) from the General Medical Council UK. Previously, Dr Adila served as a Consultant Clinical Oncologist at Weston Park Hospital, Sheffield, UK, and led the breast oncology department at Chesterfield Royal Hospital, UK. She was an active member of the multidisciplinary team, coordinating care for complex cases and contributing to research, clinical publications as well as teaching FRCR programme. One of her research – The outcome and factors predicting survival and completion of Radium 223 in metastatic castrate resistant prostate cancer was published in the Clinical Oncology Journal. She also part of the team conducting the study the COVID-RT lung which was presented in the National Cancer Research Institute conference and World Conference on Lung Cancer. Upon returning to Malaysia, she was appointed as a Consultant Clinical Oncologist and Medical Lecturer at University Malaya, where she plays a key role in both the clinical management of cancer patients and teaching in undergraduate and postgraduate medical education. She has been a dedicated trainer for the Masters in Clinical Oncology program and the MBBS undergraduate course. She has also been an invited speaker at various national and international conferences and has organized numerous educational events. Dr Adila was selected to represent Malaysia in ANZUP (Australian and New Zealand Urogenital and Prostate Cancer Trials group) Rapid Fire programme to discuss on the updates in all genito-urinary cancer treatments. She was also the chairperson and facilitator for Renal Cancer Preceptorship and Prostate Cancer Preceptorship organised by University Malaya. Dr Adila has extensive experience in treating various cancers, with expertise in breast, gynaecological, and genitourinary malignancies. Her clinical skills include individualized treatment plans utilizing chemotherapy, targeted therapy, immunotherapy, hormone therapy, advanced radiotherapy techniques using IMRT, SBRT, SRS and brachytherapy. In addition to her clinical work and academic work, Dr Adila is a passionate advocate for cancer awareness. She has led breast and prostate cancer awareness campaigns and has been involved in various charity initiatives.

Principal investigator for OP-1250-301/OPERA -01. A phase 3 Randomised , open-label study of OP-1250 Monotherapy VS standard of care for the treatment of ER+ve, HER2-ve Advanced or metastatic breast cancer following endocrine and CDK4/6 inhibitor therapy.

Sub-principal investigator for ARCHERY clinical trial. Artificial Intelligence based radiotherapy treatment planning for cervical and head and neck cancer.

Sub-principal investigator for Exelixis. A Randomised open-label phase 3 study of XL092+Nivolumab vs sunitinib in subjects with advanced or metastatic non-clear cell renal carcinoma.

• Sub-principal investigator for INAVO. A Phase III, Randomized , double blind, placebo-controlled study evaluating the efficacy and safety of inavolisib plus Palbociclib and fulvestrant versus placebo plus pablociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer.Key team member on the retrospective study comparing postmastectomy breast cancer patients with breast implant who had radiotherapy versus surgery alone between 2014-2020. Involved in developing the standard/ criteria, questionnaires for patients and data collection. The project is still on going and expected to complete in August 2021.
• First author in retrospective study on the correlation of distance between a central tumour and central structures and the effect on survival for patients receiving lung SABR (stereotactic ablative radiotherapy.) Responsible in developing the objective, data collection, perform statistical analysis and summarising the report. As a result of this study, it has demonstrated that the central location of the tumour may predict the overall survival in patients receiving stereotactic ablative radiotherapy to the lung. Abstract has been accepted by the World Conference on Lung Cancer 2021 and poster due to be presented orally on the 8th of September 2021.
• First author in retrospective study to compare dosimetric difference on treatment volume (PTV cm3) and lung V20 in patients receiving lung stereotactic ablative radiotherapy (SABR) based on use of abdominal compression. Responsible in developing the objective, data collection, perform statistical analysis and summarising the report This study has shown a non-significant trend towards reduced PTV and lung V20 in a cohort of patients whereby virtue of tumour position we would have expected the values to be larger than our comparator group. We conclude this is evidence supporting the use of abdominal compression and suggest this could be extended to other situations where reducing the PTV size may be beneficial eg treatment of more central tumours. Abstract has been accepted by the British Thoracic Oncology Group (BTOG) Conference. Poster was presented on the 23rd of April 2021.
• Co-author in auditing the changes in the management of patients having radical radiotherapy for lung cancer in the UK during the COVID-19 pandemic (COVID-RT Lung). This is a multicentre UK audit which involved patients with stage 1-3 lung cancer referred for radical radiotherapy between April and October 2020. Patients with alterations in their management during COVID19 pandemic and those who continue with standard management are included in the audit. As a result, the COVID-19 pandemic has resulted in increased use of hypofractionated and ultrahypofractionated radiotherapy schedules. The outcome was presented in the National Cancer Research Institute conference in October 2020. Abstract was submitted to the World Conference on Lung Cancer.
• Lead and first author of a retrospective study on the outcome of PARP-Inhibitor as a maintenance therapy in patients with newly diagnosed advanced ovarian cancer and platinum -sensitive recurrent ovarian cancer. An audit to assess real life experience in South Yorkshire between January 2017-December 2019. Involved in developing the criteria, data collections,
  analysing data and report summary. The results indicate that BRCA mutation patients have better outcome compared to BRCA negative patients. Overall median time between commencement of treatment and disease progression for both BRCA and non-BRCA is 8 months. The study was completed in May 2018 and was presented in the local Postgraduate Medical Education Meeting on the 16th of August 2019. This was also reviewed in the annual appraisal and received excellent feedbacks and further re-auditing will follow.
• Co-author of the retrospective study of the outcome and factors predicting survival and completion of Radium 223 in metastatic castrate resistant Prostate Cancer (mCRPC). Involved in developing the criteria, data collections and result discussions. The study has showed that overall median survival of 4.5 months for Ra-223 patients observed inferior to that reported for both the Ra-223 and placebo group (14.3 vs 11.2months) in ALSYMPCA trial. PSA does not reflect response to Ra-223 treatment. Alkaline phosphatase is a marker of bone turnover and has been used as a surrogate marker for disease response. A higher neutrophil-to-lymphocyte ratios is also an independent survival predictor in mCRPC patients receiving Ra-223. This audit was published in the Clinical Oncology Journal Volume 30, Issue 9, September 2018, Pages 548-555 2017.
• Lead and involved in audit on monitoring heart failure in GP practice in 2007. Developed the criteria, involved in data collections, summary report and presentation. The outcome of the audit has led to development of a standard Performa as part of the follow up in heart failure patients.
• National Audit in Stroke in 2006. Key team member responsible in data collections.
• Audit on Managing of Acute Gastroenteritis in children in 2006. Developed the criteria, questionnaires, data collection and analysing data. As a result, this has led to a development of a Performa that has been used in Children’s Outpatient, admission unit and A&E.

• Fellow of the Royal College of Physicians and the Royal College of Radiologists, UK
• Member of ESTRO (European Society of Radiotherapy and Oncology)
• Member of ESMO (European Society of Medical Oncology)
• Member of Malaysian Oncological Society.